NCT04476589 (PREDICT-COVID) is a clinical trial of Functional MRI in Covid19, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04476589?

NCT04476589 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04476589?

Interventions in NCT04476589: Functional MRI.

What condition does NCT04476589 study?

NCT04476589 studies Covid19, Coma, Consciousness Disorder.

Is NCT04476589 still recruiting?

NCT04476589 is currently completed. Last updated 4 April 2023.

Last reviewed 2023-04-04 · How we verify

NCT04476589: PREDICT-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostication of Recovery in Early Disorders of Consciousness After COVID-19

Completed Last updated 4 April 2023

What this trial tests

trial testing Functional MRI in Covid19 in 12 participants. Completed in 7 April 2022.

Timeline

1 July 2020

Primary endpoint
7 April 2022

7 April 2022

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	1 July 2020
Primary completion	7 April 2022
Estimated completion	7 April 2022
Sites	1 location across United States

Drugs / interventions tested

Functional MRI

Conditions studied

Covid19 — all drugs for Covid19 →
Coma — all drugs for Coma →
Consciousness Disorder — all drugs for Consciousness Disorder →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Covid19 or Coma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this research proposal is to use multimodal metrics (e.g., clinical data and advanced neuroimaging) in the early (i.e., acute hospitalization) phase of recovery from COVID-19-related disorders of consciousness to predict outcome at 3, 6, and 12 months post-hospitalization. We aim to construct an algorithm that synthesizes the results of these metrics to help predict recovery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Disorders of Consciousness Associated With COVID-19: A Prospective Multimodal Study of Recovery and Brain Connectivity.
Fischer D, Snider SB, Barra ME, Sanders WR, et al · · 2022 · cited 27× · PMID 34862317 · DOI 10.1212/wnl.0000000000013067
Imaging in the COVID-19 era: Lessons learned during a pandemic.
Sideris GA, Nikolakea M, Karanikola AE, Konstantinopoulou S, et al · · 2021 · cited 7× · PMID 34249239 · DOI 10.4329/wjr.v13.i6.192
SARS-Cov-2 Damage on the Nervous System and Mental Health.
Boulkrane MS, Ilina V, Melchakov R, Arisov M, et al · · 2022 · cited 4× · PMID 34191699 · DOI 10.2174/1570159x19666210629151303
One-Year Outcomes in Disorders of Consciousness Associated with COVID-19.
Fischer D, Edlow BL. · · 2023 · PMID 36324001 · DOI 10.1007/s12028-022-01631-y

Verify or expand the search:

Other trials of Functional MRI

Trials testing the same drug.

NCT06797661 — Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. · NA · recruiting
NCT06506019 — Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression · Phase 1 · recruiting
NCT06471179 — Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments · not yet recruiting
NCT06355284 — Overcontrol and Suicide in PTSD · active not recruiting
NCT05498532 — Functional MRI Evaluation in Pyeloureteral Junction Syndrome in Children · unknown

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04476589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 4 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04476589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing